403 related articles for article (PubMed ID: 17099880)
21. A clinical model to estimate recurrence risk in resected stage I non-small cell lung cancer.
Goodgame B; Viswanathan A; Miller CR; Gao F; Meyers B; Battafarano RJ; Patterson A; Cooper J; Guthrie TJ; Bradley J; Pillot G; Govindan R
Am J Clin Oncol; 2008 Feb; 31(1):22-8. PubMed ID: 18376223
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms.
Ruffini E; Asioli S; Filosso PL; Lyberis P; Bruna MC; Macrì L; Daniele L; Oliaro A
Ann Thorac Surg; 2009 Feb; 87(2):365-71; discussion 371-2. PubMed ID: 19161739
[TBL] [Abstract][Full Text] [Related]
23. Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer.
Yilmaz A; Ernam D; Unsal E; Demirag F; Atikcan S; Taştepe I
Arch Med Res; 2007 Oct; 38(7):764-8. PubMed ID: 17845896
[TBL] [Abstract][Full Text] [Related]
24. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
25. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells.
Ladoire S; Arnould L; Apetoh L; Coudert B; Martin F; Chauffert B; Fumoleau P; Ghiringhelli F
Clin Cancer Res; 2008 Apr; 14(8):2413-20. PubMed ID: 18413832
[TBL] [Abstract][Full Text] [Related]
26. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
Kiniwa Y; Miyahara Y; Wang HY; Peng W; Peng G; Wheeler TM; Thompson TC; Old LJ; Wang RF
Clin Cancer Res; 2007 Dec; 13(23):6947-58. PubMed ID: 18056169
[TBL] [Abstract][Full Text] [Related]
27. Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma.
Miracco C; Mourmouras V; Biagioli M; Rubegni P; Mannucci S; Monciatti I; Cosci E; Tosi P; Luzi P
Oncol Rep; 2007 Nov; 18(5):1115-22. PubMed ID: 17914561
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
29. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue.
Chaput N; Louafi S; Bardier A; Charlotte F; Vaillant JC; Ménégaux F; Rosenzwajg M; Lemoine F; Klatzmann D; Taieb J
Gut; 2009 Apr; 58(4):520-9. PubMed ID: 19022917
[TBL] [Abstract][Full Text] [Related]
30. Surfactant protein A gene deletion and prognostics for patients with stage I non-small cell lung cancer.
Jiang F; Caraway NP; Nebiyou Bekele B; Zhang HZ; Khanna A; Wang H; Li R; Fernandez RL; Zaidi TM; Johnston DA; Katz RL
Clin Cancer Res; 2005 Aug; 11(15):5417-24. PubMed ID: 16061856
[TBL] [Abstract][Full Text] [Related]
31. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer.
Yanagisawa K; Tomida S; Shimada Y; Yatabe Y; Mitsudomi T; Takahashi T
J Natl Cancer Inst; 2007 Jun; 99(11):858-67. PubMed ID: 17551146
[TBL] [Abstract][Full Text] [Related]
32. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression.
Shen LS; Wang J; Shen DF; Yuan XL; Dong P; Li MX; Xue J; Zhang FM; Ge HL; Xu D
Clin Immunol; 2009 Apr; 131(1):109-18. PubMed ID: 19153062
[TBL] [Abstract][Full Text] [Related]
33. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer patients?
Jordanova ES; Gorter A; Ayachi O; Prins F; Durrant LG; Kenter GG; van der Burg SH; Fleuren GJ
Clin Cancer Res; 2008 Apr; 14(7):2028-35. PubMed ID: 18381941
[TBL] [Abstract][Full Text] [Related]
34. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
[TBL] [Abstract][Full Text] [Related]
35. The ratio of intra-tumoral regulatory T cells (Foxp3+)/helper T cells (CD4+) is a prognostic factor and associated with recurrence pattern in gastric cardia cancer.
Kim HI; Kim H; Cho HW; Kim SY; Song KJ; Hyung WJ; Park CG; Kim CB
J Surg Oncol; 2011 Dec; 104(7):728-33. PubMed ID: 21792941
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.
Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL
Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma.
Tomsová M; Melichar B; Sedláková I; Steiner I
Gynecol Oncol; 2008 Feb; 108(2):415-20. PubMed ID: 18037158
[TBL] [Abstract][Full Text] [Related]
38. Lymph node isolated tumor cells and micrometastases in pathological stage I non-small cell lung cancer: prognostic significance.
Rena O; Carsana L; Cristina S; Papalia E; Massera F; Errico L; Bozzola C; Casadio C
Eur J Cardiothorac Surg; 2007 Dec; 32(6):863-7. PubMed ID: 17936004
[TBL] [Abstract][Full Text] [Related]
39. Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors.
Kilic A; Landreneau RJ; Luketich JD; Pennathur A; Schuchert MJ
J Surg Res; 2011 May; 167(2):207-10. PubMed ID: 19896677
[TBL] [Abstract][Full Text] [Related]
40. Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence.
Hung JJ; Hsu WH; Hsieh CC; Huang BS; Huang MH; Liu JS; Wu YC
Thorax; 2009 Mar; 64(3):192-6. PubMed ID: 19252018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
